Sentence: Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer .
Drug combination annotation:
[{'class': 'NEG', 'spans': ['Seribantumab', 'Erlotinib'], 'is_context_needed': True}]